The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Comprehensive reviews of the literature related to management and diagnosis of pheochromocytoma are available elsewhere.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
Family history or certain types of symptom profiles might indicate to a doctor that a pheochromocytoma may be present. These tumors are also linked to certain, rare genetic conditions. Diagnosis ...
During his time in Columbus, Dr. Miller published an illustrated book, “Principles of Health Preservation”, which observed ...
focused on the evaluation of postoperative management of patients with pheochromocytoma assessing hemodynamic ... that since PPGL recurrence can occur at any time after the initial diagnosis of PPGL, ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback